Abcam, ab265978, Human SEC16A (SEC16) knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
SEC16A KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 1 bp insertion in exon 3. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 1 bp insertion in exon 3,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SEC16A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SEC16A also known as SEC16 is an important component in the secretory pathway specifically in vesicle trafficking from the endoplasmic reticulum (ER) to the Golgi apparatus. This protein plays a significant role in the assembly of coat protein complex II (COPII)-coated vesicles acting as a scaffold for other components. SEC16A has a molecular mass of approximately 240 kDa. It is broadly expressed in various tissues with notable expression in cells with high secretory activity.
Biological function summary
Functions of SEC16A are critical in maintaining ER exit sites (ERES) where the budding of COPII vesicles occurs. It localizes to these ERES facilitating the formation of transport vesicles. SEC16A does not work alone; it interacts with several other proteins to form a functional multi-protein complex associated with this vesicle trafficking process. These interactions ensure the efficient transport of proteins and lipids necessary for cellular homeostasis and secretion.
Pathways
SEC16A integrates into the COPII-mediated vesicle formation pathway pivotal for protein sorting and transportation. This protein collaborates closely with the SAR1 SEC23 SEC24 SEC13 and SEC31 proteins through the vesicle formation cycle. Besides its role in COPII assembly SEC16A also contributes to the regulation of ER-Golgi transport influencing the growth factor signaling pathways that depend on the accurate delivery of their receptor components to the cell surface.
Disruptions in the function of SEC16A links to conditions like Anderson-Fabry disease and congenital disorders of glycosylation. Abnormal vesicle trafficking due to SEC16A impairment can lead to an accumulation of metabolites or misfolded proteins that disrupt cellular function. SEC16A's relationship with proteins involved in lipid metabolism and glycosylation supports the role in these disorders. Understanding the behaviour of SEC16A in these contexts may contribute to targeted therapeutic strategies.